Table 3.

Predictive Power and Agreement of Methylene Blue Injection Test, Capping Trial, and Antegrade Nephrostogram in Predicting NT Removal Before Discharge Home

	Methylene blue	Capping trial	Combined	ANG
Sensitivity	77.6% (63.4%–88.2%)	96.2% (87%–99.5%)	75.0% (60.4%–86.4%)	86.8% (74.7%–94.5%)
Specificity	65.2% (42.7%–83.6%)	35.5% (19.2%–54.6%)	69.6% (47.1%–86.8%)	69.2% (48.2%–85.7%)
PPV	82.6% (68.6%–92.2%)	71.8% (59.9%–81.9%)	83.7% (69.3%–93.2%)	85.2% (72.9%–93.4%)
NPV	57.7% (36.9%–76.6%)	84.6% (54.6%–98.1%)	57.1% (37.2%–75.5%)	72.0% (50.6%–87.9%)
Likelihood ratio (+)	2.23 (1.25–3.98)	1.49 (1.14–1.95)	2.46 (1.3–4.67)	2.82 (1.57–5.07)
Likelihood ratio (−)	0.34 (0.19–0.63)	0.11 (0.03–0.45)	0.36 (0.21–0.63)	0.19 (0.09–0.40)
ROC area	0.714 (0.598–0.830)	0.659 (0.569–0.748)	0.723 (0.608–0.837)	0.780 (0.679–0.882)
kappa	0.413	0.361	0.422	0.566